Drug News

Added 7 days ago Drug news

Data for Exparel results in high rates of early discharge and patient satisfaction for total knee or hip arthroplasty

Pacira Pharmaceuticals, Inc. announced new data showing that a patient-optimizing, opioid-sparing enhanced recovery after surgery (ERAS) pathway, which includes intraoperative...

Added 6 days ago Drug news

FDA approves Dupixent to treat adolescents with atopic dermatitis

The FDA has approved Dupixent (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose...

Added 12 hours ago Drug news

FDA requires partial hold on trials for Venclexta

AbbVie has announced the FDA has placed a partial clinical hold on all clinical trials evaluating venetoclax (Venclexta /Venclyxto) for...

Added 12 hours ago Drug news

FDA approves Sunosi to improve wakefulness in adult patients

Jazz Pharmaceuticals plc announced that the FDA approved Sunosi (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness...

Added 12 hours ago Drug news

FDA approves Optimizer Smart system for heart failure

The FDA has approved the Optimizer Smart system, from Impulse Dynamics, for treating patients with chronic, moderate-to-severe heart failure who...

Added 12 hours ago Drug news

Eisai and Biogen discontinue phase III trials, ENGAGE and EMERGE

Biogen and Eisai, Co., Ltd. announced the decision to discontinue the global Phase III trials, ENGAGE and EMERGE, designed to...

Added 1 day ago Drug news

OG 217SC filed with the FDA for type 2 diabetes

Novo Nordisk announced the submission of two New Drug Applications (NDAs) to the FDA for OG 217SC (oral semaglutide), the...

Added 1 day ago Drug news

Ozempic filed with FDA for risk reduction in MACE

Novo Nordisk has filed a supplemental NDA (sNDA) with the FDA for once-weekly Ozempic (semaglutide) injection 0.5 mg or 1...

Added 1 day ago Drug news

Phase III JAVELIN Ovarian PARP 100 study is discontinued

Merck KGaA and Pfizer Inc. have announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating...

Added 1 day ago Drug news

FDA approves Zulresso to treat postpartum depression

Sage Therapeutics announced the FDA has approved Zulresso (brexanolone) injection for the treatment of postpartum depression (PPD). Zulresso is the...

Search all news articles